A new study finds no evidence of benefit from a malaria drug promoted as a treatment for CCP virus infection.
Hydroxychloroquine did not lower the risk of dying or needing a breathing tube in a comparison that involved nearly 1,400 patients treated at Columbia University in New York, researchers reported on May 7 in the New England Journal of Medicine.
